Bal Pharma Limited (NSE:BALPHARMA)

India flag India · Delayed Price · Currency is INR
92.01
-0.55 (-0.59%)
Aug 13, 2025, 3:30 PM IST

United States Steel Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212017 - 2021
Period Ending
Aug '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2017 - 2021
1,4621,3141,4321,0501,599797
Upgrade
Market Cap Growth
-12.94%-8.20%36.34%-34.31%100.65%72.70%
Upgrade
Enterprise Value
2,8782,6372,7582,0312,5871,830
Upgrade
Last Close Price
92.5683.9090.3965.76104.7851.65
Upgrade
PE Ratio
20.4318.2219.3740.8328.4916.80
Upgrade
PS Ratio
0.500.430.420.350.570.32
Upgrade
PB Ratio
1.891.702.071.652.731.49
Upgrade
P/TBV Ratio
2.372.132.231.792.931.60
Upgrade
P/FCF Ratio
-86.0012.11-8.724.20
Upgrade
P/OCF Ratio
-6.476.28-5.973.57
Upgrade
EV/Sales Ratio
0.980.870.810.670.920.73
Upgrade
EV/EBITDA Ratio
9.658.929.498.5411.777.49
Upgrade
EV/EBIT Ratio
14.9213.3312.3111.6617.3310.81
Upgrade
EV/FCF Ratio
-172.5523.32-14.129.65
Upgrade
Debt / Equity Ratio
1.971.972.052.091.822.12
Upgrade
Debt / EBITDA Ratio
5.105.154.715.404.684.48
Upgrade
Debt / FCF Ratio
-99.5612.03-5.825.97
Upgrade
Asset Turnover
-0.931.071.061.121.05
Upgrade
Inventory Turnover
-1.662.132.072.562.41
Upgrade
Quick Ratio
-0.470.610.500.520.50
Upgrade
Current Ratio
-1.071.151.091.111.08
Upgrade
Return on Equity (ROE)
-9.87%11.20%4.29%10.20%9.55%
Upgrade
Return on Assets (ROA)
-3.77%4.43%3.80%3.73%4.42%
Upgrade
Return on Capital (ROIC)
5.50%5.61%6.86%6.02%5.63%6.34%
Upgrade
Return on Capital Employed (ROCE)
-17.00%19.20%16.80%15.70%19.30%
Upgrade
Earnings Yield
4.89%5.49%5.16%2.45%3.51%5.95%
Upgrade
FCF Yield
-1.16%8.26%-15.41%11.46%23.81%
Upgrade
Dividend Yield
1.30%1.43%1.33%1.52%0.95%1.94%
Upgrade
Payout Ratio
-26.48%21.22%60.55%26.41%-
Upgrade
Buyback Yield / Dilution
-0.85%-0.11%-0.73%-5.86%-4.39%-0.19%
Upgrade
Total Shareholder Return
0.45%1.32%0.60%-4.33%-3.43%1.75%
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.